​
​

Intra-Cellular Therapies (ITCI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Intra-Cellular Therapies Revenue Highlights

Latest Revenue (Y)

$462.18M

Latest Revenue (Q)

$175.38M

Main Segment (Y)

Product

Intra-Cellular Therapies Revenue by Period

Intra-Cellular Therapies Revenue by Year

DateRevenueChange
2023-12-31$462.18M85.51%
2022-12-31$249.13M204.91%
2021-12-31$81.71M262.65%
2020-12-31$22.53M37071.49%
2019-12-31$60.61K100.00%
2018-12-31--100.00%
2017-12-31$245.84K-25.66%
2016-12-31$330.70K261.96%
2015-12-31$91.36K-84.17%
2014-12-31$577.30K-78.91%
2013-12-31$2.74M-12.22%
2012-12-31$3.12M-

Intra-Cellular Therapies generated $462.18M in revenue during NA 2023, up 85.51% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Intra-Cellular Therapies Revenue by Quarter

DateRevenueChange
2024-09-30$175.38M8.67%
2024-06-30$161.39M11.41%
2024-03-31$144.87M10.16%
2023-12-31$131.51M4.53%
2023-09-30$125.81M14.24%
2023-06-30$110.13M16.25%
2023-03-31$94.73M8.35%
2022-12-31$87.43M21.65%
2022-09-30$71.87M30.50%
2022-06-30$55.07M58.46%
2022-03-31$34.76M36.21%
2021-12-31$25.52M18.10%
2021-09-30$21.61M13.68%
2021-06-30$19.01M22.00%
2021-03-31$15.58M25.60%
2020-12-31$12.40M68.33%
2020-09-30$7.37M292.81%
2020-06-30$1.88M112.56%
2020-03-31$882.52K1355.98%
2019-12-31$60.61K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--100.00%
2017-12-31$5.05K-83.56%
2017-09-30$30.75K-73.20%
2017-06-30$114.74K20.42%
2017-03-31$95.29K-2.66%
2016-12-31$97.89K2144.27%
2016-09-30$4.36K-98.09%
2016-06-30$228.44K100.00%
2016-03-31--100.00%
2015-12-31$30.66K100.00%
2015-09-30--100.00%
2015-06-30$57.39K1631.22%
2015-03-31$3.31K-90.82%
2014-12-31$36.11K-70.98%
2014-09-30$124.41K-43.25%
2014-06-30$219.24K30.66%
2014-03-31$167.79K-79.72%
2013-12-31$827.53K23.89%
2013-09-30$667.96K100.00%
2013-06-30--100.00%
2013-03-31$-129.64M-

Intra-Cellular Therapies generated $175.38M in revenue during Q3 2024, up 8.67% compared to the previous quarter, and up 159.25% compared to the same period a year ago.

Intra-Cellular Therapies Revenue Breakdown

Intra-Cellular Therapies Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20
Grant$2.19M$1.18M$2.10M$282.23K
Product$462.18M$249.13M$81.71M$22.53M

Intra-Cellular Therapies's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (99.53%), and Grant (0.47%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Product$175.16M$144.84M$131.51M$125.81M$110.13M$94.73M$87.43M$71.87M$55.07M$34.76M$25.52M$21.61M$19.01M$15.58M$12.40M$7.37M$1.88M$882.52K
Grant$216.00K$23.00K$593.00K$363.00K$664.00K$575.00K$436.00K-$505.00K$241.00K$154.90K$601.04K$1.04M$299.42K$50.52K-$30.75K$200.96K

Intra-Cellular Therapies's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (99.88%), and Grant (0.12%).

Intra-Cellular Therapies Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AMRXAmneal Pharmaceuticals$2.39B$702.47M
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
PCRXPacira BioSciences$674.98M$168.57M
AMPHAmphastar Pharmaceuticals$593.24M$188.82M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$91.59M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DVAXDynavax$232.28M$79.34M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
AQSTAquestive Therapeutics$50.58M$13.54M
CYTHCyclo Therapeutics$1.08M$123.10K

ITCI Revenue FAQ

What is Intra-Cellular Therapies’s yearly revenue?

Intra-Cellular Therapies's yearly revenue for 2023 was $462.18M, representing an increase of 85.51% compared to 2022. The company's yearly revenue for 2022 was $249.13M, representing an increase of 204.91% compared to 2021. ITCI's yearly revenue for 2021 was $81.71M, representing an increase of 262.65% compared to 2020.

What is Intra-Cellular Therapies’s quarterly revenue?

Intra-Cellular Therapies's quarterly revenue for Q3 2024 was $175.38M, a 8.67% increase from the previous quarter (Q2 2024), and a 39.40% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $161.39M, a 11.41% increase from the previous quarter (Q1 2024), and a 46.55% increase year-over-year (Q2 2023). ITCI's quarterly revenue for Q1 2024 was $144.87M, a 10.16% increase from the previous quarter (Q4 2023), and a 52.92% increase year-over-year (Q1 2023).

What is Intra-Cellular Therapies’s revenue growth rate?

Intra-Cellular Therapies's revenue growth rate for the last 3 years (2021-2023) was 465.64%, and for the last 5 years (2019-2023) was 762401.44%.

What are Intra-Cellular Therapies’s revenue streams?

Intra-Cellular Therapies's revenue streams in c 23 are Grant, and Product. Grant generated $2.2M in revenue, accounting 0.47% of the company's total revenue, up 85.70% year-over-year. Product generated $462.18M in revenue, accounting 99.53% of the company's total revenue, up 85.51% year-over-year.

What is Intra-Cellular Therapies’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Intra-Cellular Therapies was Product. This segment made a revenue of $462.18M, representing 99.53% of the company's total revenue.